Redeye comments on the changes in CLS’s Board of Directors.
Redeye comments on OncoZenge’s announcement that SAFE has approved its SEK30.
Redeye updates its base case of Synact following the directed share issue and new programme in polym...
Redeye revises its financial forecast and valuation of Polygiene following the change of lead analys...
Synthetic MR:s förseningar i lanseringen av SyMRI 3D har lett till ett svagt första kvartal 2025, me...
Q2e: -4.5% organic sales growth, 9% adj. EBITA margin Expect continued caution in Sweden Trading at ...
Redeye comments on IRLAB’s announcement of a guaranteed SEK 136m rights issue aimed at advancing its...
Nettoomsättningen för det första kvartalet uppgick till 4,6 (3,5) miljoner kronor.
Administer announced that it intends to acquire the financial, payroll and software services busines...
Redeye thinks the phase II study is now on track, with the last patient recruited and preliminary re...
Redeye comments on today’s mandatory offer from Arise’s largest shareholder, the CA Group.
Redsense växer stabilt med stigande omsättning och förbereder lansering av Clamp i Storbritannien.
Q-linea provides a business update before closing and reports its Q2 result later in July.
Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre...
Forward-looking metrics a bit on the soft side Competitor and peer Accenture reported its Q3'25 repo...
Biovica continues to increase 12m rolling IVD test sales in Q4 of SEK 0.
Alisa Bank issued a profit warning, with continued weaker demand driving lower volumes.
Redeye re-initiates coverage of marketing technology company Eniro Group, perceiving the company to ...
Redeye provides a comment on Verve’s announcement of a directed share issue which strengthens the co...
Redeye comments on the topline data from the phase II study POSITANO, which investigates the effect ...
